NEWS

PRESS RELEASE | 2023

OCMS is attending Biopharm America on September 13 to the 14th.

BioPharm America brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level discussion. Thomas Halpern chief of operations at OCMS Bio will be attending this event. OCMS continuously innovates and enhances our platform to deliver more highly accurate and differentiated data for our partners with multiple offerings to assist through the life of discovery.  We welcome the opportunity to explore research or development collaborations at this conference. Use the button below to schedule an introductory meeting with Thom.

​

EXTERNAL ARTICLE | 2023

Detecting Emerging Viral Variants Through Rapid Antibody Discovery and Characterization  READ MORE

PRESS RELEASE | 2022

OCMS Bio Moves Laboratory to Malvern

Malvern, PA –  OCMS Bio moves laboratory operations to Great Valley Corporate Center in Malvern, Pennsylvania. The move will better accommodate recent growth of OCMS Bio and enhance work with collaborators in the area. OCMS Bio provides groundbreaking antibody tools and services based on its proprietary on-cell mAb screening technology enabling discovery, optimization and IP protection of monoclonal antibodies.  For more information, contact info@ocms.bio.

VIDEO | 2022

Patent Protection Program

​

EXTERNAL ARTICLE | 2022

Detecting Emerging Viral Variants Through Rapid Antibody Discovery and Characterization.  READ MORE

EXTERNAL ARTICLE | 2022

OCMS Bio has been recognized as the "Best Monoclonal Antibody Tools Engineering Service Provider 2022" by Global Health & Pharma!  READ MORE

EXTERNAL ARTICLE | LIVE WEBINAR 2022

Detecting emerging viral variants through rapid antibody discovery and characterization.  RESERVE YOUR SPOT

EXTERNAL ARTICLE | 2021

Philadelphia’s ability to track COVID-19 variants — and the nation’s — is hobbled by a lack of resources.  READ MORE

EXTERNAL ARTICLE | 2021

Immunologist 'cautiously optimistic' about omicron COVID-19 variant.  READ MORE

EXTERNAL ARTICLE | 2021

LIMR develops 'groundbreaking' rapid test to detect Delta variant in Covid-19 patients.  READ MORE

EXTERNAL ARTICLE | 2020

Guiding light: Main Line startup taps Lankenau Institute’s glow tech to make antibodies.  READ MORE

EXTERNAL ARTICLE | 2019

Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening.  READ MORE

EXTERNAL ARTICLE | NO DATE

On-cell antibody display from hybridoma cells.  READ MORE